Rheumatology INFO

Rheumatology INFO Promoting Autoimmune Rheumatic Diseases awareness It is intended for patients and the general public for rheumatologic disease awareness as well.
(1)

Rheumatology INFO is an official page, aimed to share updated news about Autoimmune Rheumatic Diseases and also serve as an ongoing educative platform for Physicians, Rheumatologist, other Medical Health care professionals, interns and students. Comments, blogs, Qs, experience and articles sharing are gratefully accepted. Welcome to my page of 100% info sharing, sit back and stay a while!

  nephritis treatment summary
16/11/2025

nephritis treatment summary

2025   Guidelinefor the Treatment of Systemic   Erythematosus⏩ uniform treatment with hydroxychloroquine⏩ early introduc...
16/11/2025

2025 Guideline
for the Treatment of Systemic Erythematosus

⏩ uniform treatment with hydroxychloroquine
⏩ early introduction of conventional and/or biologic immunosuppressive
⏩ -related morbidity and mortality, and minimize medication-related toxicities

NEW PROTOCOL FOR DIAGNOSING   IntroductionHow to determine what criteria needed to change?What are the significant chang...
12/11/2025

NEW PROTOCOL FOR DIAGNOSING

Introduction

How to determine what criteria needed to change?

What are the significant changes?

New /American College of Rheumatology Classification Criteria for

In Conclusion

◾️New Protocol for Diagnosing Lupus

The American College of Rheumatology’s ( # # ), in 1997, approved a specific set of criteria for the diagnosis of systemic lupus erythematosus (SLE). Recently, however, in collaboration with the European League Against (EULAR), these criteria have been significantly revised. Read on to learn more about these important changes and how they can affect how lupus is diagnosed.

◾️Introduction

The ACR’s classification criteria for SLE have been used worldwide as a cornerstone for determining the diagnosis of lupus, yet it had not been revised in over 20 years. As research and clinical studies advanced, there was a need to have a more interdisciplinary and international approach to lupus diagnosis, and to develop more specific and sensitive ways to classify the most important criteria. In response, the ACR collaborated with EULAR to develop new criteria that include a weighted system for calculating the probability of the presence of SLE as opposed to other systemic autoimmune disease such as Sjögren’s syndrome. It can be difficult to differentiate between those two diseases using the 1997 ACR criteria, for example, as both diseases often and significantly overlap each other.

A 1999 article published in the journal Lupus discussed the need for change and the evolution of classification criteria over time in order for that information to “reflect and facilitate a better understanding of the disease.” At that time, researchers of the 1999 article recommended the following for future classification revisions:

The revisions should include individuals who were originally diagnosed with SLE, but would not meet the criteria in future studies.

They should place as much value on the degree of symptoms, organ involvement and damage, disease duration and activity as on the number of criteria met or unmet.

The periodical revision of criteria should at some point include a simple weighted system that “may more accurately reflect clinical practice.”

These recommendations were used to inform a new study that would look into revising the outdated criteria.

❓What needed to change?

Several lupus research centers across Europe worked on this international initiative, with the ACR and EULAR, to analyze the existing criteria and write new ones. According to Dr. Jack Cush of RheumNow – News and Information the study was conducted in four phases:

📍Assessing the feasibility of including antinuclear antibody (ANA) as new criteria. Researchers analyzed several databases that included over 13,000 individuals from several studies and found a 97.8% ANA sensitivity, convincing researchers of the necessity of ANA inclusion in the new classification.

📍Determining how to reduce criteria. The number of criteria was reduced from 43 to 21. This simplified things, but also included differentiating between “required” criteria – those that were absolutely necessary for a lupus diagnosis – and others called “additive” criteria.

📍Discussing how to define and weigh new criteria. A group of SLE patient advocates, a steering committee and international SLE experts collectively determined how to redefine and weigh the final reduced list of criteria through “[achieving] consensus on classifying a case vignette as SLE.”

📍Deciding how to refine weighting and threshold scores with a new cohort of subjects. Experts determined a “data-driven threshold for classification” and evaluated information on individuals thought to have SLE but who were below the threshold and “misclassified” against individuals who unequivocally had SLE yet still missed classification requirements. Experts again refined the proposed weighing system, rounding the weights to whole numbers, according to the findings from their evaluation. A steering committee “unanimously endorsed” the new system.

📍The new classification reflects the “largest international, collaborative SLE classification effort to date.” Twenty-three international lupus research centers engaged in this study and subsequent revisions, each selecting individuals with SLE and those without to partake in the research. A group of 1,001 individuals were reviewed using the proposed new criteria while a group of 1,270 individuals were reviewed using existing criteria in order to compare the difference in diagnoses from one set of criteria to the other.

◾️According to an article published in the September 2019 issue of Annals of the Rheumatic Diseases, the study took place in the Department of Rheumatology, Hopitaux Universitaires Paris Sud, which is a reference center for “rare systemic autoimmune disease.”

❓What are the significant changes from 1999 to 2020 criteria?

Dr. Cush notes the following significant changes to the new criteria:

◾️Criteria is chosen from seven clinical categories including: constitutional, hematologic, neuropsychiatric, mucocutaneous, serosal, musculoskeletal and renal.

◾️Criteria is chosen from three immunologic categories including: antiphospholipid antibodies, complement proteins and SLE-specific antibodies.

◾️Criteria is weighted from two to ten.

◾️Derivation and validation sensitivity and specificity percentages have increased from the previous criteria.

◾️Individuals with ≥ 10 points are classified as having SLE.

◾️The 1997 classification outlined 11 criteria that are common to SLE. If an individual met at least 4 of the criteria, the likelihood was high that they had SLE, prompting their healthcare practitioner to perform additional tests and create treatment plans based on the analysis. Researchers of the 2019 study published in the journal Annals of the Rheumatic Diseases note that the new criteria was developed with “multidisciplinary and international input,” and has “excellent sensitivity and specificity.”

◾️New EULAR/American College of Rheumatology Classification Criteria for SLE

The following is the new SLE EULAR/ACR classification criteria:

⬇️ SEE CRITERIA CHART BELOW ⬇️

◾️A supplement to this new classification gives specific examples of how the new rating system works in diagnosing an individual with SLE. The examples show a practical application of the new system in order to understand how it works. The following is an excerpt from the supplement that puts the rating system into practice to give a clearer picture of its use:

📍30 year female patient with new onset polyarthritis. Anti-CCP antibodies negative, no erosions on plain x-ray films, Hep-2 ANA 1:320 (homogenous), anti-dsDNA antibodies positive in ELISA and verified by CLIFT (Crithidia luciliae immunofluorescence test)

📍Entry criterion: Fulfilled (ANA ever positive by Hep-2 ≥1:80 or equivalent test)

📍Clinical criterion: Fulfilled (Joint involvement): 6 points

📍Attribution to SLE: Correct (Anti-CCP is negative, no more likely cause of arthritis)

📍Lupus specific antibody: anti-dsDNA positive (CLIFT has ≥90% proven specificity against relevant disease controls, ELISA anti-dsDNA alone usually not): 6 points

💜ANA entry + 12 points: ➡️ This patient should be classified as having SLE.
◾️In Conclusion

This new classification may seem confusing and overwhelming at first. We strongly suggest speaking with your trusted healthcare practitioner about these changes and if they will affect your diagnosis and treatment. Learning as much as you can about the new system will prepare you to advocate for yourself and other individuals with lupus who may be confused or scared about what these changes may mean. Rest assured that researchers have your best interests at heart – this study and resulting classification update “reflect current thinking about SLE and provide an improved foundation for SLE research.”

Source: Kaleidoscope Fighting Lupus

By Liz Heintz

💜 NEW CRITERIAS FOR DIAGNOSING ⬇️⬇️⬇️

Ever seen a patient with a positive ANA but negative ENA — and wondered what it really means? 🤔Here’s a quick guide to d...
10/11/2025

Ever seen a patient with a positive ANA but negative ENA — and wondered what it really means? 🤔
Here’s a quick guide to decode this common rheumatology dilemma 👇

Not everything with “lupus” is  ! 🐺❌Some diseases carry the name but have nothing to do with systemic lupus erythematosu...
31/08/2025

Not everything with “lupus” is ! 🐺❌

Some diseases carry the name but have nothing to do with systemic lupus erythematosus ( ). Let’s clear the confusion

1️⃣ Lupus vulgaris
➡️ Chronic cutaneous TB 🦠
➡️ Painful nodules & ulcers, often disfiguring (“wolf-bite” scars)

2️⃣ Lupus pernio
➡️ Chronic sarcoidosis of the skin
➡️ Violaceous plaques on nose, cheeks, ears

3️⃣ Lupus miliaris disseminatus faciei (LMDF)

➡️ Rare granulomatous papules, esp. around eyelids/mid-face
➡️ Heal with pits/scars

4️⃣ Lupus anticoagulant
➡️ A misnamed autoantibody
➡️ Causes clotting + pregnancy loss (Antiphospholipid Syndrome)
🚫 Over half of patients don’t even have lupus!

So next time you hear “lupus”, remember:
👉 Sometimes it’s TB, sarcoid, granulomas, or antibodies — but not lupus erythematosus!

Names confuse, diseases don’t connect.



30/08/2025

The effect of NSAID exposure on kidney function by comparing it to a state of no NSAID exposure.digitalcommons.uri.edu/c...
29/08/2025

The effect of NSAID exposure on kidney function by comparing it to a state of no NSAID exposure.

digitalcommons.uri.edu/cgi/viewconten…

How do you treat challenging cases of antibody-mediated glomerular diseases? This   article explains the options, their ...
29/08/2025

How do you treat challenging cases of antibody-mediated glomerular diseases? This article explains the options, their efficacy, and possible future directions for care. kidney/ disease
pub/CJASN0843

29/08/2025

💊 𝗛𝘆𝗱𝗿𝗼𝘅𝘆𝗰𝗵𝗹𝗼𝗿𝗼𝗾𝘂𝗶𝗻𝗲 (𝗛𝗖𝗤) is best known for treating lupus and rheumatoid arthritis – but did you know it may also help people with 𝗮𝗻𝘁𝗶𝗽𝗵𝗼𝘀𝗽𝗵𝗼𝗹𝗶𝗽𝗶𝗱 𝘀𝘆𝗻𝗱𝗿𝗼𝗺𝗲 (𝗔𝗣𝗦)?

📌 𝗔 𝟮𝟬𝟮𝟱 𝗿𝗲𝘃𝗶𝗲𝘄 𝗳𝗼𝘂𝗻𝗱 𝗛𝗖𝗤 𝗰𝗮𝗻:
• Reduce inflammation and clotting
• Improve blood vessel function
• Help lower risk of pregnancy complications
• Work 𝙖𝙡𝙤𝙣𝙜𝙨𝙞𝙙𝙚 anticoagulants – not instead of them

🧪 A major European trial (HYPATIA) is now testing whether HCQ improves pregnancy outcomes in people with antiphospholipid antibodies.

⚠️ It’s not suitable for everyone, and decisions must be made with your specialist.

🔗 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲 𝘃𝗶𝗮 𝘁𝗵𝗲 𝗹𝗶𝗻𝗸 𝗯𝗲𝗹𝗼𝘄 👇

Address

Port Louis Town

Telephone

+23059076469

Website

Alerts

Be the first to know and let us send you an email when Rheumatology INFO posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Rheumatology INFO:

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category